SOUTH SAN FRANCISCO (dpa-AFX) - The European Commission has approved label expansion of Roche's (RHHBY) Hemlibra to include people with moderate haemophilia A in the European Union.Hemlibra, already
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia A without. | December 11, 2022
Baxalta, a subsidiary of Japan-headquartered pharmaceutical company Takeda, has asked the US Court of Appeals for the Federal Circuit to overturn a decision that invalidated its antibody patent.